Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival of Trial-Like and Non-Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP).
Ramaswamy A, Kulkarni A, John G, Rauthan A, Patil S, Duseja A, Talwar V, Rajappa SJ, Ghadyalpatil N, Wadhawan M, Shukla A, Krishna VM, Srinivas S, Taneja S, Sravani KM, Rathi S, Bhargava P, Ostwal V. Ramaswamy A, et al. Among authors: patil s. JCO Glob Oncol. 2023 Sep;9:e2300215. doi: 10.1200/GO.23.00215. JCO Glob Oncol. 2023. PMID: 38033275 Free PMC article.
The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours-A real-world multicentric study from India.
Abraham G, Noronha V, Rajappa S, Agarwal A, Batra U, Somani N, Raja T, Patil S, Kaushal AM, Joshi A, Radhakrishnan V, Singh N, Babu G, Tewani R, Baghmar S, Dodagoudar C, Ananthakrishnan R, Haragadde Poppareddy S, Sharma V, Menon N, M Patil V, Joshi A, Gupta S, Prabhash K, Bajpai J. Abraham G, et al. Among authors: patil s. Int J Cancer. 2022 Mar 15;150(6):1045-1052. doi: 10.1002/ijc.33868. Epub 2021 Nov 25. Int J Cancer. 2022. PMID: 34751432 Free article.
CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.
Prabhash K, Biswas B, Khurana S, Batra U, Biswas G, Advani SH, Mohapatra PN, Rajappa S, Sharma A, Patil S, Dattatreya PS, Roy R, Almel S, Goyal G, Warrier N. Prabhash K, et al. Among authors: patil s. Indian J Cancer. 2022 Mar;59(Supplement):S11-S18. doi: 10.4103/ijc.ijc_438_21. Indian J Cancer. 2022. PMID: 35343188 Free article.
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, Wang Y, Varadhachary A, Zhu J, Malik R. Parikh PM, et al. Among authors: patil s. J Clin Oncol. 2011 Nov 1;29(31):4129-36. doi: 10.1200/JCO.2010.34.4127. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969509 Clinical Trial.
Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India.
Nimmagadda RB, Digumarti R, Nair R, Bhurani D, Raina V, Aggarwal S, Patil S, Gogoi PK, Sundaram S, Goswami C, Apte S, Chakravarthy S, Pathak A. Nimmagadda RB, et al. Among authors: patil s. Indian J Med Paediatr Oncol. 2013 Oct;34(4):299-304. doi: 10.4103/0971-5851.125250. Indian J Med Paediatr Oncol. 2013. PMID: 24604961 Free PMC article.
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
Digumarti R, Wang Y, Raman G, Doval DC, Advani SH, Julka PK, Parikh PM, Patil S, Nag S, Madhavan J, Bapna A, Ranade AA, Varadhachary A, Malik R. Digumarti R, et al. Among authors: patil s. J Thorac Oncol. 2011 Jun;6(6):1098-103. doi: 10.1097/JTO.0b013e3182156250. J Thorac Oncol. 2011. PMID: 21532506 Free article. Clinical Trial.
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India.
Parikh PM, Bhattacharyya GS, Biswas G, Krishnamurty A, Doval D, Heroor A, Sharma S, Deshpande R, Chaturvedi H, Somashekhar SP, Babu G, Reddy GK, Sarkar D, Desai C, Malhotra H, Rohagi N, Bapna A, Alurkar SS, Krishna P, Deo SVS, Shrivastava A, Chitalkar P, Majumdar SK, Vijay D, Thoke A, Udupa KS, Bajpai J, Rath GK, Dattatreya PS, Bondarde S, Patil S. Parikh PM, et al. Among authors: patil s. South Asian J Cancer. 2021 Dec 31;10(4):213-219. doi: 10.1055/s-0041-1742080. eCollection 2021 Dec. South Asian J Cancer. 2021. PMID: 34984198 Free PMC article.
5,348 results